Abstract Search

ea0098c17 | Clinical – Chemo/SSA/Biologics | NANETS2023

Argentinian registry of gastric neuroendocrine tumors: A closer look at type 1

Oviedo Ana , Luca Romina , Bestani Claudia , Rodriguez Andres , Waisberg Federico , Ypa Carla , Catani Greta , Acosta Andrea , Maquieira Julian , Pombo Teresa , Kujaruk Mirta , Mendez Guillermo , O'Connor Juan

Background: Gastric neuroendocrine tumors (gNETs) are relatively uncommon. Represent up to 23% of all digestive neuroendocrine neoplasms. The majority are incidentally diagnosed from histology of simple gastric polyps identified at endoscopy. There are 3 groups of gNETs: types 1, 2 and 3 with different pathogeneses, biological and clinical behaviors. It is worth mentioning that recent reports suggest a fourth type of gNETs1. Type I represents 7580%...

1 shares

ea0098c42 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Treatment with Lutetium in a real-world setting: How does it affect patient experience and their time-toxicity?

Romina Luca Maria , Cecilia Vazquez Eliana , Waisberg Federico , Catani Greta , Oviedo Ana , Musumeci Martina , Rodriguez Andres , Bortz Marcos , Esteso Federico , Chacon Matias , Manuel Oconnor Juan , Racioppi Silvina

Background: Lutetitum-177 (Lu-DOTATE) is an approved treatment regimen for patients with advanced neuroendocrine tumors (NETs). Improving patient experience is one of main goals of a cancer treatment plan. "Time-toxicity" describes the period that patients spend in doing administrative or medical procedures, including medical visits, scans, lab analyses, emergency room admissions, drug applications and hospitalizations. Modern therapies are usually approved after an im...

0 shares

Endocrine Abstracts

Argentinian registry of gastric neuroendocrine tumors: A closer look at type 1

Treatment with Lutetium in a real-world setting: How does it affect patient experience and their time-toxicity?

BiosciAbstracts